tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CLDX Stock Latest News

Celldex Expands Into Asthma: Early CDX-622 Trial Signals New Growth Angle for CLDX
Company AnnouncementsCelldex Expands Into Asthma: Early CDX-622 Trial Signals New Growth Angle for CLDX
9d ago
CLDX
Celldex Advances Barzolvolimab Into Phase 3 for Chronic Inducible Urticaria: What Investors Should Watch
PremiumCompany Announcements
Celldex Advances Barzolvolimab Into Phase 3 for Chronic Inducible Urticaria: What Investors Should Watch
23d ago
CLDX
Celldex price target raised to $24 from $21 at Barclays
PremiumThe Fly
Celldex price target raised to $24 from $21 at Barclays
1M ago
CLDX
Celldex Therapeutics Advances Barzolvolimab Study for Chronic Urticaria
PremiumCompany Announcements
Celldex Therapeutics Advances Barzolvolimab Study for Chronic Urticaria
2M ago
CLDX
Celldex Therapeutics Completes Promising Phase 2 Study on Chronic Inducible Urticaria Treatment
PremiumCompany Announcements
Celldex Therapeutics Completes Promising Phase 2 Study on Chronic Inducible Urticaria Treatment
2M ago
CLDX
These 3 Unknown Stocks Can Double, Say Five-Star Analysts – 12/11/2025
PremiumMarket NewsThese 3 Unknown Stocks Can Double, Say Five-Star Analysts – 12/11/2025
2M ago
CLDX
CNTA
Celldex’s Promising Market Opportunity: Buy Rating Backed by Phase III Trial and Revenue Projections
Premium
Ratings
Celldex’s Promising Market Opportunity: Buy Rating Backed by Phase III Trial and Revenue Projections
2M ago
CLDX
Celldex’s Strategic Advancement in Phase 3 Trials for Barzolvolimab: A Promising Opportunity in Chronic Inducible Urticaria Treatment
Premium
Ratings
Celldex’s Strategic Advancement in Phase 3 Trials for Barzolvolimab: A Promising Opportunity in Chronic Inducible Urticaria Treatment
2M ago
CLDX
Celldex announces initiation of Phase 3 trial of barzolvolimab
PremiumThe Fly
Celldex announces initiation of Phase 3 trial of barzolvolimab
2M ago
CLDX
Celldex’s Promising Clinical Progress and Strategic Initiatives Drive Buy Rating
PremiumRatings
Celldex’s Promising Clinical Progress and Strategic Initiatives Drive Buy Rating
3M ago
CLDX
Celldex’s Promising Future: Strong Pipeline and Financial Position Drive Buy Rating
PremiumRatings
Celldex’s Promising Future: Strong Pipeline and Financial Position Drive Buy Rating
3M ago
CLDX
Celldex price target lowered to $21 from $25 at Barclays
PremiumThe Fly
Celldex price target lowered to $21 from $25 at Barclays
3M ago
CLDX
Celldex’s Promising Pipeline and Strategic Advancements Justify Buy Rating
PremiumRatingsCelldex’s Promising Pipeline and Strategic Advancements Justify Buy Rating
3M ago
CLDX
Celldex Therapeutics Reports Q3 2025 Results and Pipeline Progress
Premium
Company Announcements
Celldex Therapeutics Reports Q3 2025 Results and Pipeline Progress
3M ago
CLDX
Optimistic Buy Rating for Celldex Driven by Promising Clinical Developments and Strong Financial Position
Premium
Ratings
Optimistic Buy Rating for Celldex Driven by Promising Clinical Developments and Strong Financial Position
3M ago
CLDX
Celldex reports Q3 EPS ($1.01), consensus (89c)
PremiumThe Fly
Celldex reports Q3 EPS ($1.01), consensus (89c)
3M ago
CLDX
Celldex appoints Lawver as Chief Commercial Officer
PremiumThe Fly
Celldex appoints Lawver as Chief Commercial Officer
3M ago
CLDX
Celldex’s Promising Phase II Trial Results Justify Buy Rating
PremiumRatings
Celldex’s Promising Phase II Trial Results Justify Buy Rating
3M ago
CLDX
Celldex’s Promising Phase 2 Trial Results and Strong Financial Position Support Buy Rating
PremiumRatings
Celldex’s Promising Phase 2 Trial Results and Strong Financial Position Support Buy Rating
3M ago
CLDX
Celldex’s Barzolvolimab Shows Promising Phase 2 Results, Justifying Buy Rating
PremiumRatingsCelldex’s Barzolvolimab Shows Promising Phase 2 Results, Justifying Buy Rating
3M ago
CLDX
Celldex announces additional data on barzolvolimab
Premium
The Fly
Celldex announces additional data on barzolvolimab
3M ago
CLDX
Celldex presents results from Barzolvolimab Phase 2 Study in ColdU, SD
Premium
The Fly
Celldex presents results from Barzolvolimab Phase 2 Study in ColdU, SD
3M ago
CLDX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >